Clinical trials: Treatment Resistant Psychosis
Schizophrenia
DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still a difficult clinical issue at present.
- Trial name
- NCT02532686
- Testing
- DAAOI-2
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Insulin Resistance
Salsalate for Insulin Resistance in Schizophrenia
Being obese is a common problem for people with schizophrenia. People with schizophrenia are more likely to be overweight compared to the general population.
- Trial name
- NCT01182727
- Testing
- salsalate
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, Baltimore
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Refractory Schizophrenia
Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia
Studies using repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory auditory hallucinations (AH) in schizophrenia have shown promise.
- Trial name
- NCT01386918
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizotypal Disorder
Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis
The aim of the COPUS study is to investigate, whether it is possible to recruit and retain young people with first-episode psychosis, to an 8 week supervised High-Intensity Functional Training intervention (HIFT) (i.e.
- Conditions
- Schizophrenia, Schizotypal Disorder, First Episode Psychosis, Psychotic Disorders
- Trial name
- COPUS (NCT03409393)
- Testing
- The COPUS intervention, Usual Care (OPUS treatment)
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Schizophrenia
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).
- Trial name
- NCT03652974
- Testing
- sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine, amisulpride with Clozapine
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Shanghai Mental Health Center
Treatment Resistant Schizophrenia
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%.
- Trial name
- NCT05944510
- Testing
- Dextromethorphan
- Where
- India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society.
- Trial name
- Phase3 (NCT04054778)
- Testing
- Avatar Therapy, Cognitive Behavioral Therapy
- Where
- Canada
- Volunteers
- 136 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Schizophrenia
The Optimal Treatment for Treatment-resistant Schizophrenia
The Optimal Treatment for Treatment-resistant Schizophrenia
- Trial name
- NCT02926976
- Testing
- Risperidone with Clozapine, Aripiprazole with Clozapine, sodium valproate with Clozapine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Mental Health Center
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Refractory Schizophrenia, Super Refractory Schizophrenia
Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia
Introduction: In spite of recent advances in schizophrenia treatment, 30% of patients still do not respond properly to antipsychotic therapy.
- Trial name
- SSURECT (NCT02049021)
- Testing
- MECTA SPECTRUM 5000Q ECT
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Schizophrenia, Schizoaffective Disorder
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
Atypical antipsychotic medications, such as olanzapine, cause metabolic side effects, including weight gain, extra fat around the middle of the body, high blood sugar, and high cholesterol.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity
- Trial name
- NCT00512070
- Testing
- olanzapine and melatonin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Schizophrenia, Auditory Hallucinations
A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine
The primary outcome of this study is to evaluate the effects of low frequency subthreshold repetitive Transcranial Magnetic Stimulation applied to the left temporoparietal cortex of patients with refractory schizophrenia on the…
- Trial name
- NCT01015001
- Testing
- (1Hz) rTMS applied over the left temporoparietal cortex
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Schizophrenia
Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia
Auditory Hallucinations (AH) are experienced by 50 to 70% of subjects with schizophrenia. Almost a quarter of patients are medication resistant to such symptoms.
- Trial name
- rTMS (NCT02175251)
- Testing
- high frequency (20Hz), low frequency (1Hz)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia, Obsessive-Compulsive Symptoms
Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With Schizophrenia
This is a study to evaluate the efficacy of rTMS for relief of obsessive-compulsive symptoms in patients with schizophrenia.
- Trial name
- NCT02105064
- Testing
- Active rTMS
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Treatment-resistant Schizophrenia
Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia
This pilot study aims to investigate the use of MRI-guided low-intensity focused ultrasound (LIFU) to modulate neuronal activity within the thalamus in human subjects with treatment-resistant schizophrenia.
- Trial name
- NCT05259306
- Testing
- Insightec Exablate Neuro MR-guided focused ultrasound transducer
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia, Insulin Resistance
- Trial name
- NCT00401089
- Testing
- Panax Ginseng
- Where
- 4 sites in Canada, United Kingdom
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant Schizophrenia (TRS).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT02533232
- Testing
- Minocycline
- Where
- 4 sites in Pakistan
- Volunteers
- 60 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia Disorders, Treatment Resistant Hallucinations
Cognitive and Metacognitive Evaluation in VR-Based Avatar Therapy for Psychosis
This study aims to evaluate the relationship between cognitive, metacognitive and social cognition variables in patients with psychosis undergoing VR-based Avatar Therapy for the treatment of auditory hallucinations.
- Trial name
- Meta-VR-AVATAR (NCT07091344)
- Testing
- VR-Based Avatar Therapy with Cognitive and Metacognitive Assessments
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Sant Joan de Déu